Physician profile
Ashley N Strickland
NPI 1376308783
$864.84
in general payments reported to CMS, 2019-2025
20 companies · $303 in 2025
The $303 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $561 · 2025: $303.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $691 · Education: $174.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $690.85 |
| Education | $173.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $269.99 | 2024-2025 | Padcev, Vyloy, Xtandi |
| Daiichi Sankyo INC. | $73.81 | 2024 | Enhertu |
| Merck Sharp & Dohme LLC | $72.65 | 2024-2025 | Keytruda, Welireg |
| Ipsen Biopharmaceuticals, INC | $64.71 | 2024-2025 | Somatuline Depot, Onivyde |
| Stemline Therapeutics INC. | $39.07 | 2024-2025 | Orserdu |
| Genentech USA, INC. | $36.56 | 2024 | Polivy, Tecentriq, Phesgo |
| Aveo Pharmaceuticals, INC. | $33.87 | 2025 | |
| Celgene Corporation | $31.26 | 2024 | Reblozyl |
| Geron Corporation | $27.51 | 2024 | Rytelo |
| Pharmaessentia USA Corporation | $26.11 | 2024 | Besremi |
| Azurity Pharmaceuticals, INC. | $23.28 | 2025 | Danziten |
| Beone Medicines USA, INC. | $22.75 | 2025 | Brukinsa |
| Taiho Oncology, INC. | $21.56 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.92 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.96 | 2024 | Opdualag |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $18.47 | 2024 | Ultomiris |
| Catalyst Pharmaceuticals, INC. | $17.97 | 2024 | |
| Genzyme Corporation | $16.82 | 2024 | |
| Glaxosmithkline, LLC. | $15.47 | 2025 | Ojjaara |
| Janssen Biotech, INC. | $13.10 | 2024 | Talvey, Tecvayli, Darzalex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Strickland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.